Parabilis Medicines, Inc. Common Stock (PBLS) News
Latest headlines that mention PBLS, newest first · each headline opens the original publisher
- Last price
- $25.03
- Day change
- +2.41%
- Next earnings
- 2026-11-12
PBLS headlines
latest coverageParabilis Medicines is ambitious, but it has Regeneron on its side already.
Parabilis Medicines, a Cambridge, Massachusetts, biotech innovator in oncology, reported a notable insider buy amid ongoing development of cancer therapies.
Parabilis Medicines Inc. shares jumped 58% in its trading debut, after the company raised nearly $745 million in an upsized US initial public offering that priced above its marketed range and a private placement.
Parabilis Medicines Inc., a clinical-stage cancer drug developer, raised nearly $745 million in an upsized US initial public offering that priced above its marketed range, and a private placement.
Parabilis Medicines, a clinical-stage cancer drug developer, is seeking to raise $475 million in an initial public offering.
PBLS news alerts
Get an alert by email or push when a new headline mentions PBLS.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.